ISRCTN43697583招募中2 期
Scientific title as of 05/12/2018: The efficacy of Rifapentine 900mg/d plus Moxifloxacin 400mg/d given for 14 or 7 days against Onchocerciasis: a randomized, parallel-group, open-label, phase II pilot trial. Previous scientific title: The efficacy of Rifapentine 600mg/d plus Moxifloxacin 400mg/d given for 14 or 7 days against Onchocerciasis: a randomized, parallel-group, open-label, phase II pilot trial.
Kumasi Centre for Collaborative Research (KCCR)0 个研究点目标入组 80 人开始时间: 2015年4月17日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Participant inclusion criteria as of 05/12/2018:
- •1. Willingness to participate in the study by signing the Informed Consent Form (ICF)
- •2. 18-55 years
- •3. Body weight > 45kg
- •4. Presence of at least 1 medium-sized onchocercoma detected by palpation
- •5. Mf-positive
- •6. Good general health without any clinical condition requiring medication
- •7. No previous history of tuberculosis
- •8. Participants with the ability to follow study instructions and are likely to attend and complete all required visits
- •Previous participant inclusion criteria:
- •1. Men and Women
- •2. 18-55 years
- •3. Body weight > 45kg
- •4. Presence of at least 3 onchocercomata detected by palpation
- •5. Mf-positive
- •6. Good general health without any clinical condition requiring long-term medication
- •7. No previous history of tuberculosis
- •8. Participants with the ability to follow study instructions and are likely to attend and complete all required visits
- •9. Willingness to participate in the study by signing the Informed Consent Form (ICF)
排除标准
- •Participant exclusion criteria as of 05/12/2018:
- •General Exclusion Criteria:
- •1. Participants not able to give consent
- •2. Participants who are unable to understand the nature, scope, significance and consequences of this clinical trial
- •3. Participants taking any concomitant medication
- •4. Known history of hypersensitivity to the investigational drug or to drugs with a similar chemical struc-ture (moxifloxacin or any member from the quinolone class, rifapentine or any member of the rifamycins, doxycycline or any member of the tetracyclines)
- •5. Simultaneous participation in any clinical trial involving administration of an investigational medicinal product within 30 days prior to clinical trial beginning
- •6. Participants with a physical or psychiatric condition which at the investigator’s discretion may put the subject at risk, may confound the trial results, or may interfere with the subject’s participation in this clinical trial
- •7. Known or persistent abuse of medication, drugs or alcohol
- •Exclusion criteria regarding special restrictions for females:
- •1. Pregnant women
- •2. Breastfeeding women
- •3. Females of childbearing potential, who are not willing or able to use methods to prevent a pregnancy for the entire treatment duration in addition to hormonal contraception (e.g. condoms) unless they are surgically sterilized / hysterectomized or there are any other criteria considered sufficiently reliable by the investigator in individual cases.
- •Indication specific exclusion criteria:
- •1. History or clinical signs of tuberculosis or treatment against TB
- •2. History of porphyria
- •3. History or clinical signs of arrhythmia
- •4. Bradycardia (< 50bpm)
- •5. QT-prolongation (QT interval >440 msec for men and >460 msec for women)
- •6. History of tendinitis or tendon rupture
- •7. History of rheumatoid arthritis
- •8. History of myasthenia gravis or polio
- •9. History of cerebral disorder (e.g. epilepsy)
- •10. History of photosensitivity/phototoxicity
- •11. History of Diabetes mellitus (in addition urine examination for glucose)
- •12. Evidence of clinically significant neurological, cardiac, pulmonary, hepatic or renal disease as far as can be assessed by history of participants, physical examination, and/or laboratory examinations
- •13. Evidence of acute Hepatitis A and of acute or chronic Hepatitis B or C
- •14. Laboratory evidence of liver disease (AST, ALT, gammaGT, Bilirubin greater than the upper limit of normal)
- •15. Laboratory evidence of renal disease (serum creatinine greater than 1.5 times upper limit of normal)
- •16. Laboratory evidence of low or high potassium level (potassium level < 3.6 or > 5.2)
- •17. Laboratory evidence of leucopenia (< lower limit of normal)
- •Previous participant exclusion criteria:
- •1. Pregnant women
- •2. Breastfeeding women
- •3. Participants not able to give consent
- •4. Participants without legal capacity who are unable to understand the nature, scope, significance and consequences of this
研究者
相似试验
已完成
不适用
Oral iron, intravenous iron or discontinuation of therapy for older adults with treatment unresponsive iron deficiency anaemiaIron deficiency anaemiaHaematological DisordersISRCTN98371961niversity of Aberdeen5
已完成
不适用
Effects of acupuncture on heart rate variability in adult tinnitus patientsEar, Nose and ThroatTinnitusISRCTN58013563Beijing Municipal Health Bureau (China)30
已完成
不适用
Public title as of 17/09/2018 'Helpmedoit!' an app, web and social support based weight loss intervention for adults with obesity Previous public title: 'Helpmedoit!' a web and text based intervention to facilitate social support to achieve and maintain health-related change in physical activity and dietary behaviour.Nutritional, Metabolic, EndocrineObesityISRCTN85615983HS Greater Glasgow and Clyde (UK)109
进行中（未招募）
2 期
Chemo-immunotherapy before and after surgery for peritoneal metastases of large bowel cancerCancerISRCTN15977568Catharina Hospital (Netherlands)358
已完成
不适用
GPOD pH test Vs pH measurement to assess Nasogastric Tube (NGT) positioutrition or medication administered via a nasogastric tubeISRCTN14985496GPod Global177